Publications by authors named "Jan Valka"

Claim this Profile
R
Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic.
Barbora Dluhošová, Benjamín Víšek, Jan Válka, Martin Čerňan, Ľubomír Minařík

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner, Maximillian-Alexander Röhnert, Christian Rausch

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, Sven Zukunft, Barbora Weinbergerová, Jan Valka

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking aberrant glycosylation of plasma glycoproteins with progression of myelodysplastic syndromes: a study based on plasmonic biosensor and lectin array.
Leona Chrastinová, Ondřej Pastva, Markéta Bocková, Hana Kovářová, Eliška Ceznerová

Sci Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Barbora Weinbergerová, Ivo Demel, Benjamin Víšek, Jan Válka, Martin Čerňan

Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome.
Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Katarina Szikszai, Monika Belickova, Jan Valka

Cells· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene.
Jan Valka, Jitka Vesela, Hana Votavova, Michaela Dostalova-Merkerova, Zuzana Urbanova

Oncol Res Treat· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Differential diagnosis of anemia].
Jan Válka, Jaroslav Čermák

Vnitr Lek· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.
Jan Valka, Jitka Vesela, Hana Votavova, Michaela Dostalova-Merkerova, Zuzana Horakova

Eur J Haematol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
M Monika Belickova, Michaela Dostalova Merkerova, Hana Votavova, Jan Valka, Jitka Vesela

Int J Hematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
Monika Belickova, Jitka Vesela, Anna Jonasova, Barbora Pejsova, Hana Votavova, Jan Valka

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis